首页> 美国卫生研究院文献>Scientific Reports >A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability
【2h】

A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability

机译:基于化合物的蛋白质组学方法公开了15-酮基缩水甘油生成素甲酯作为具有抗增殖能力的新型PPARγ部分激动剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proteomics based approaches are emerging as useful tools to identify the targets of bioactive compounds and elucidate their molecular mechanisms of action. Here, we applied a chemical proteomic strategy to identify the peroxisome proliferator-activated receptor γ (PPARγ) as a molecular target of the pro-apoptotic agent 15-ketoatractyligenin methyl ester (compound >1). We demonstrated that compound >1 interacts with PPARγ, forms a covalent bond with the thiol group of C285 and occupies the sub-pocket between helix H3 and the β-sheet of the ligand-binding domain (LBD) of the receptor by Surface Plasmon Resonance (SPR), mass spectrometry-based studies and docking experiments. >1 displayed partial agonism of PPARγ in cell-based transactivation assays and was found to inhibit the AKT pathway, as well as its downstream targets. Consistently, a selective PPARγ antagonist (GW9662) greatly reduced the anti-proliferative and pro-apoptotic effects of >1, providing the molecular basis of its action. Collectively, we identified >1 as a novel PPARγ partial agonist and elucidated its mode of action, paving the way for therapeutic strategies aimed at tailoring novel PPARγ ligands with reduced undesired harmful side effects.
机译:基于蛋白质组学的方法正在成为有用的工具,可用于识别生物活性化合物的靶标并阐明其分子作用机理。在这里,我们应用了一种化学蛋白质组学策略,将过氧化物酶体增殖物激活受体γ(PPARγ)鉴定为促细胞凋亡剂15-酮基化酶原甲酯(化合物> 1 )的分子靶标。我们证明了化合物> 1 与PPARγ相互作用,与C285的硫醇基形成共价键,并占据了螺旋H3和β-折叠的配体结合域(LBD)之间的亚型。表面等离子体共振(SPR),基于质谱的研究和对接实验对受体进行了鉴定。 > 1 在基于细胞的反式激活分析中显示PPARγ的部分激动作用,并被发现抑制AKT途径及其下游靶标。一致地,选择性PPARγ拮抗剂(GW9662)大大降低了> 1 的抗增殖和促凋亡作用,为其作用提供了分子基础。我们共同确定了> 1 为新型PPARγ部分激动剂,并阐明了其作用方式,为旨在减少不良有害副作用的新型PPARγ配体的治疗策略铺平了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号